Skip to main content

Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Table 2 Laboratory and clinical parameters of the patients during IVIG therapy

From: Intravenous immunoglobulin treatment of four patients with juvenile polyarticular arthritis associated with persistent parvovirus B19 infection and antiphospholipid antibodies

           B19 DNA IgG anti-PL   
Patient Sample ESR (mm/h) WBC/ml RBC/ml Hb (g/dl) CRP (mg/dl) CK (U/l) Arthritis (joints) Total IgG (mg/dl) Serum SF Anti-CL Anti-PS Anti-β2GPI VAS (doctor) VAS (parents)
1 1 5 7.96 4.21 12.0 neg. 15 2 414 pos. na - - ++ 5 3
  2 nd nd nd nd nd nd nd 1832 neg. na - - + nd nd
  3 5 6.88 4.25 12.3 neg. 21 0 1430 pos. na - - - 1 1
  4 nd nd nd nd nd nd nd 2480 neg. na - - - nd nd
  5 9 9.58 4.36 12.3 neg. 16 0 1406 neg. na - - (+) 1 1
  6 9 7.0 4.4 12.2 neg. 17 0 nd neg. na - - - 1 1
2 1 35 8.57 4.82 11.5 0.7 103 4 1450 neg. na - - + 4 4
  2 nd nd nd nd nd nd nd 3040 neg. na - - + n.d nd
  3 37 7.47 4.43 11.3 2.6 33 1 468 neg. na - - - 5 6
  3 nd nd nd nd nd nd nd 3680 neg. na + ++ ++ nd nd
  5 40 6.18 4.47 11.6 1.5 30 2 2020 pos. na - - - 4 6
  6 42 7.91 4.63 11.7 6.4 27 2 nd neg. na - - - 5 7
3 1 15 6.33 4.84 13.5 0.5 20 0 864 pos. na - - - 5 5
  2 nd nd nd nd nd nd nd 3600 pos. na - - - nd nd
  3 12 6.96 4.61 13.1 0.7 25 0 1604 pos. na - - - 5 3
  4 nd nd nd nd nd nd nd 2420 pos. pos. - ++ + nd nd
  5 34 9.87 4.83 13.5 0.9 25 1 1734 neg. na - - - 5 3
  6 36 7.50 4.90 14.2 neg. 20 0 nd neg. na - - - 3 2
4 1 30 8.99 4.32 12.5 1.5 22 5 1014 pos. na - - ++ 4 4
  2 nd nd nd nd nd nd nd 2540 neg. na - ++ ++ nd nd
  3 40 7.27 4.05 12.1 neg. 32 1 1724 pos. na - ++ ++ 2 2
  4 nd nd nd nd nd nd nd 3420 neg. na - ++ ++ nd nd
  5 21 6.45 4.07 12.6 neg. 33 1 1788 neg. na - - - 1 1
  6 10 6.50 4.35 13.3 neg. 20 0 nd neg. na - - + 1 1
  1. The patients were examined before and after the first treatment cycle (day 1, samples 1; day 5, samples 2), before and after the second treatment cycle (day 1, samples 3; day 5, samples 4), and 1 month (samples 5) and 9 months (samples 6) after the end of the second cycle. In addition to laboratory parameters including the amplification of parvoviral DNA derived from serum or synovial fluid, antiphospholipid antibodies (IgG anti-PL: anti-CL, anti-cardiolipin; anti-PS, anti-phosphatidylserine; anti-β2GPI, anti-β2-glycoprotein I; -, no reaction; +, positive, ++, strongly positive), doctors' and parents' global assessments of overall disease activity were recorded on a visual analogue scale (VAS) ranging from 0 (healthy) to 10 (severely affected). CK, creatine kinase; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; Hb, haemoglobin; IVIG, high-dose intravenous immunoglobulin; na, not available; nd, not determined; RBC, red blood cells; SF, synovial fluid; WBC, white blood cells.